Diprivan is owned by Fresenius Kabi Usa.
Diprivan contains Propofol.
Diprivan has a total of 2 drug patents out of which 0 drug patents have expired.
Diprivan was authorised for market use on 02 October, 1989.
Diprivan is available in injectable;injection dosage forms.
The generics of Diprivan are possible to be released after 01 June, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8476010||FRESENIUS KABI USA||Propofol formulations with non-reactive container closures|| |
(1 year, 10 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|FRESENIUS KABI USA||Propofol formulations with non-reactive container closures|| |
(2 years from now)
Market Authorisation Date: 02 October, 1989
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic